Pharmacoeconomic review report: Siponimod (Mayzent) (Novartis pharmaceuticals Canada Inc.) indication : secondary-progressive multiple sclerosis
Siponimod (Mayzent) is a sphingosine 1-phosphate receptor modulator. This submission relates to the Health Canada-approved indication for the treatment of adults with secondary-progressive multiple sclerosis (SPMS) with active disease, evidenced by relapses or imaging features characteristic of mult...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2013, September 2020
|
| Edition: | Version: Final |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references